Séminaire d'Aurélien SERANDOUR, PhD - Nantes, France

CRCINA, équipe 11 dirigée par Stéphane Minvielle

Multiple myeloma is characterized by proliferative malignant plasma cells within the bone marrow. The 5-year survival is about 50% often after several relapses. New sequencing technologies combined with bioinformatics allow us to deepen our knowledge of the disease. Our lab has accumulated for the last decade about 2000 DNA and RNA multiple myeloma samples. These were purified from bone marrow biopsies using anti-CD138 beads. We are currently mapping genome-wide the epigenetic DNA mark 5-hmC (5-hydroxymethylCytosine) to identify active genomic regions. Combined with RNA-seq, we hope to identify non-coding regions implicated in myeloma initiation or progression. At the same time, we are also starting to analyse bone marrow biopsies using high-throughput single-cell RNA-seq (Chromium, 10x Genomics) in order to fully characterize the transcriptional landscape of the myeloma and of its neighbouring normal cells.